

SWIXX AND BIOCRYST PARTNER FOR ORLADEYO® (berotralstat) IN CENTRAL AND EASTERN EUROPE

SWIXX ANNOUNCEMENT NO. 52

January 24th, 2023

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of an exclusive Distribution and Supply Agreement with BioCryst Pharmaceuticals, Inc. Under the Agreement, Swixx will exclusively distribute and commercialize Orladeyo® (berotralstat) in the EU countries: Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia. In addition, Swixx is appointed to exclusively distribute and commercialize Orladeyo® in non-EU markets of Bosnia and Herzegovina, North Macedonia and Serbia.

Orladeyo® is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older¹.

“It is a privilege for Swixx to partner with BioCryst in CEE”, said Dezso Martha, COO of Swixx. “We are confident we can successfully leverage our unparalleled Rare Disease capabilities across CEE countries to support access to Orladeyo® for patients with hereditary angioedema. Our experienced Rare Disease teams will strive to bring this long-term prophylactic therapy to the patients who need it most.”

Dr. Laur Saar, Medical, Regulatory and Pharmacovigilance Director at Swixx outlined: “There are significant unmet needs for new treatments of HAE, which affect every HAE patient in a number of ways. We look forward to working with the CEE medical community to raise awareness about new scientific data on preventive long-term oral treatment options that will help healthcare providers and patients manage HAE, working in close collaboration with BioCryst.”

About Swixx BioPharma AG

Swixx operates fully-owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries including Belarus, Kazakhstan, Moldova and Uzbekistan. With over 1200 employees and sales which exceeded 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma in the Central, Eastern and Southeastern regions of Europe. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG
vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

References:

¹European Medicines Agency, Summary of product characteristics, ORLADEYO® (berotralstat). Available at: https://www.ema.europa.eu/en/documents/product-information/orladeyo-epar-product-information_en.pdf. Last accessed: January 2023.